David Fiorentino, MD, PhD
Academic Appointments
- Associate Professor - Med Center Line, Dermatology
- Member, Bio-X
- Associate Professor - Med Center Line (By courtesy), Medicine - Immunology & Rheumatology
Key Documents
Contact Information
-
Clinical Offices
Medical Dermatology 450 Broadway ST Pav B FL 4 MC 5338 Redwood City, CA 94063 Tel Work (650) 723-6316 Fax (650) 721-3476
- Academic Offices
Administrative Contact Olena Mykhaylichenko Administrative Associate Email Tel Work 650-721-7193Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Dermatology
- Autoimmune Diseases
Administrative Appointments
- Founding member, North American Rheumatologic Dermatology Society (NARDS) (2006 - present)
- Scientific advisory board, National Psoriasis Foundation (2008 - present)
- Advisory board, The Myositis Association (2008 - present)
- Advisory board, Lupus Foundation of America (2008 - present)
- Steering Committee, Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA) (2006 - present)
- Editorial Board, Journal of The American Academy of Dermatology (2004 - present)
Honors and Awards
- Clinical Immunology Faculty Scholarship Award, Center for Clinical Immunology at Stanford (2003-2006)
- Medical Dermatology Development Award, Dermatology Foundation (2004-2007)
Professional Education
| Medical Education: | Stanford University School of Medicine CA (1998) |
| Residency: | Stanford University School of Medicine CA (2002) |
| Board Certification: | Dermatology, American Board of Dermatology (2002) |
| Internship: | University of Colorado School of Medicine CO (1999) |
| Ph.D.: | Stanford University, Cancer Biology (1998) |
| M.D.: | Stanford University (1998) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
I am interested in the pathophysiology, natural history and treatment of patients with immune-mediated skin disease. In conjunction with Dr. Lorinda Chung, Assistant Professor of Rheumatology, we have developed a multi-disciplinary autoimmune skin disease clinic. This weekly clinic is dedicated to the management of patients with rheumatic skin disease, such as lupus erythematosus, scleroderma, dermatomyositis, vasculitis, and psoriasis/psoriatic arthritis.
Part of my research focus is to conduct clinical trials in patients with all types of immunologic skin disease. The skin is the only target organ in which you can actually visualize the direct effects of inflammation, without the need for surrogate markers. We are particularly interested in studying in vivo effects of targeted therapeutic agents in order to better understand the biology of different types of cutaneous inflammation. To this end, we conduct phase I, II, and III trials in patients with a diverse array of inflammatory skin diseases.
We are also creating a longitudinal clinical and tissue bank derived from patients seen in our clinics. One focus of this translational research effort is to understand the pathophysiology of dermatomyositis. This is a particularly challenging clinical model, as it is known to be associated with internal malignancy in up to 30% of patients. In addition, there is considerable heterogeneity between patients, in terms of skin versus muscle inflammation. We are using microarray technology to identify novel targets for disease as well as molecular signatures that will help clinicians to better manage their patients with this devastating disease. We believe that, from these studies, it will be possible to make accurate clinical predictions regarding: risk of internal malignancy, risk of lung disease, or response to various therapeutic agents.
Clinical Trials
- Not Recruiting A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
- Not Recruiting A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
- Recruiting A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
- Recruiting A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
Publications
- Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. Br J Dermatol. 2013; (1): 210-2
- Localized cutaneous fibrosing disorders. Rheum Dis Clin North Am. 2013; (2): 347-64
- A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2012; (4): 220-8
- Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 2012; (2): 346-9
- Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol. 2012; (5): 375-81
- Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012; (7): 1143-50
Help